Role of mismatch repair proteins in the processing of cisplatin interstrand cross-links

DNA Repair

Volumn 35, Issue , 2015, Pages 126-136

  Sawant, Akshada ^a   Kothandapani, Anbarasi ^a   Zhitkovich, Anatoly ^b   Sobol, Robert W ^c,d,e,f   Patrick, Steve M ^g  

^a UNIVERSITY OF TOLEDO   (United States)

^b BROWN UNIVERSITY   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^e UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^f University of South Alabama Mitchell Cancer Institute   (United States)

^g WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

ATPase; BER; Cisplatin; MMR; Resistance

Indexed keywords

ADENOSINE TRIPHOSPHATASE; CISPLATIN; MISMATCH REPAIR PROTEIN; MYRICETIN; OXALIPLATIN; PROTEIN MUTS; ANTINEOPLASTIC AGENT; CROSS LINKING REAGENT; DNA BINDING PROTEIN; G-T MISMATCH-BINDING PROTEIN; MLH1 PROTEIN, HUMAN; MSH2 PROTEIN, HUMAN; MUTL PROTEIN HOMOLOG 1; NUCLEAR PROTEIN; PROTEIN MSH2; SIGNAL TRANSDUCING ADAPTOR PROTEIN;

ARTICLE; CELL SURVIVAL; COMPLEX FORMATION; CONTROLLED STUDY; DNA CROSS LINKING; DNA STRAND BREAKAGE; ENZYME ACTIVITY; HUMAN; HUMAN CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN PROCESSING; ANIMAL; DOUBLE STRANDED DNA BREAK; DRUG RESISTANCE; GENE SILENCING; GENETICS; METABOLISM; MISMATCH REPAIR; MOUSE; TUMOR CELL LINE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CISPLATIN; CROSS-LINKING REAGENTS; DNA BREAKS, DOUBLE-STRANDED; DNA MISMATCH REPAIR; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; GENE KNOCKDOWN TECHNIQUES; HUMANS; MICE; MUTL PROTEIN HOMOLOG 1; MUTS HOMOLOG 2 PROTEIN; NUCLEAR PROTEINS;

EID: 84945138331     PISSN: 15687864     EISSN: 15687856     Source Type: Journal    
DOI: 10.1016/j.dnarep.2015.10.003     Document Type: Article

References (43)

1. Iyer R.R., Pluciennik A., Burdett V., Modrich P.L. DNA mismatch repair: functions and mechanisms. Chem. Rev. 2006, 106:302-323.
2. Fink D., Zheng H., Nebel S., Norris P.S., Aebi S., Lin T.P., Nehme A., Christen R.D., Haas M., MacLeod C.L., Howell S.B. In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair. Cancer Res. 1997, 57:1841-1845.
3. Wang J.Y.J., Edelmann W. Mismatch repair proteins as sensors of alkylation DNA damage. Cancer Cell 2006, 9:417-418.
4. Pani E., Stojic L., El-Shemerly M., Jiricny J., Ferrari S. Mismatch repair status and the response of human cells to cisplatin. Cell Cycle 2007, 6:1796-1802.
5. Fink D., Nebel S., Aebi S., Zheng H., Cenni B., Nehme A., Christen R.D., Howell S.B. The role of DNA mismatch repair in platinum drug resistance. Cancer Res. 1996, 56:4881-4886.
6. Fink D., Aebi S., Howell S.B. The role of DNA mismatch repair in drug resistance. Clin. Cancer Res. 1998, 4:1-6.
7. Jiricny J. The multifaceted mismatch-repair system. Nat. Rev. Mol. Cell Biol. 2006, 7:335-346.
8. Mojas N., Lopes M., Jiricny J. Mismatch repair-dependent processing of methylation damage gives rise to persistent single-stranded gaps in newly replicated DNA. Genes Dev. 2007, 21:3342-3355.
9. Yamada M., ORegan E., Brown R., Karran P. Selective recognition of a cisplatin-DNA adduct by human mismatch repair proteins. Nucleic Acids Res. 1997, 25:491-496.
10. Mello J.A., Acharya S., Fishel R., Essigmann J.M. The mismatch-repair protein hMSH2 binds selectively to DNA adducts of the anticancer drug cisplatin. Chem. Biol. 1996, 3:579-589.
11. Yoshioka K.I., Yoshioka Y., Hsieh P. ATR kinase activation mediated by MutS alpha and MutL alpha in response to cytotoxic O-6-methylguanine adducts. Mol. Cell 2006, 22:501-510.
12. Zhu G., Lippard S.J. Photoaffinity labeling reveals nuclear proteins that uniquely recognize cisplatin-DNA interstrand cross-links. Biochemistry 2009, 48:4916-4925.
13. Takahashi M., Koi M., Balaguer F., Boland C., Goel A. MSH3 mediates sensitization of colorectal cancer cells to cisplatin, oxaliplatin, and a poly(ADP-ribose) polymerase inhibitor. J. Biol. Chem. 2011, 286.
14. Park J.M., Huang S., Tougeron D., Sinicrope F.A. MSH3 mismatch repair protein regulates sensitivity to cytotoxic drugs and a histone deacetylase inhibitor in human colon carcinoma cells. PLoS One 2013, 8:e65369.
15. Tentori L., Muzi A., Dorio A.S., Dolci S., Campolo F., Vernole P., Lacal P.M., Praz F., Graziani G. MSH3 expression does not influence the sensitivity of colon cancer HCT116 cell line to oxaliplatin and poly(ADP-ribose)polymerase (PARP) inhibitor as monotherapy or in combination. Cancer Chemother. Pharmacol. 2013, 72:117-125.
16. Kothandapani A., Dangeti V.S.M.N., Brown A.R., Banze L.A., Wang X.H., Sobol R.W., Patrick S.M. Novel role of base excision repair in mediating cisplatin cytotoxicity. J. Biol. Chem. 2011, 286:14564-14574.
17. Kothandapani A., Sawant A., Dangeti V.S.M.N., Sobol R.W., Patrick S.M. Epistatic role of base excision repair and mismatch repair pathways in mediating cisplatin cytotoxicity. Nucleic Acids Res. 2013, 41:7332-7343.
18. Trivedi R.N., Wang X.H., Jelezcova E., Goellner E.M., Tang J.B., Sobol R.W. Human methyl purine DNA glycosylase and DNA polymerase beta expression collectively predict sensitivity to temozolomide. Mol. Pharmacol. 2008, 74:505-516.
19. Reynolds M.F., Peterson-Roth E.C., Bespalov I.A., Johnston T., Gurel V.M., Menard H.L., Zhitkovich A. Rapid DNA double-strand breaks resulting from processing of Cr-DNA cross-links by both MutS dimers. Cancer Res. 2009, 69:1071-1079.
20. Arora S., Kothandapani A., Tillison K., Kalman-Maltese V., Patrick S.M. Downregulation of XPF-ERCC1 enhances cisplatin efficacy in cancer cells. DNA Repair 2010, 9:745-753.
21. De Silva I.U., Mchugh P.J., Clingen P.H., Hartley J.A. Defects in interstrand cross-link uncoupling do not account for the extreme sensitivity of ERCC1 and XPF cells to cisplatin. Nucleic Acids Res. 2002, 30:3848-3856.
22. Zdraveski Z.Z., Mello J.A., Farinelli C.K., Essigmann J.M., Marinus M.G. MutS preferentially recognizes cisplatin- over oxaliplatin-modified DNA. J. Biol. Chem. 2002, 277:1255-1260.
23. Eastman A., Schulte N. Enhanced DNA-repair as a mechanism of resistance to cis-diamminedichloroplatinum(Ii). Biochemistry 1988, 27:4730-4734.
24. De Silva I.U., Mchugh P.J., Clingen P.H., Hartley J.A. Defects in interstrand cross-link uncoupling do not account for the extreme sensitivity of ERCC1 and XPF cells to cisplatin. Nucleic Acids Res. 2002, 30:3848-3856.
25. Wu Q., Vasquez K.M. Human MLH1 protein participates in genomic damage checkpoint signaling in response to DNA interstrand crosslinks, while MSH2 functions in DNA repair. PLoS Genet. 2008, 4.
26. Avdievich E., Reiss C., Scherer S.J., Zhang Y., Maier S.M., Jin B., Hou H., Rosenwald A., Riedmiller H., Kucherlapati R., Cohen P.E., Edelmann W., Kneitz B. Distinct effects of the recurrent Mlh1(G67R) mutation on MMR functions, cancer, and meiosis. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:4247-4252.
27. Lin D.P., Wang Y.X., Scherer S.J., Clark A.B., Yang K., Avdievich E., Jin B., Werling U., Parris T., Kurihara N., Umar A., Kucherlapati R., Lipkin M., Kunkel T.A., Edelmann W. An Msh2 point mutation uncouples DNA mismatch repair and apoptosis. Cancer Res. 2004, 64:517-522.
28. Wu Q., Christensen L.A., Legerski R.J., Vasquez K.M. Mismatch repair participates in error-free processing of DNA interstrand crosslinks in human cells. EMBO Rep. 2005, 6:551-557.
29. Wynne P., Newton C., Ledermann J., Olaitan A., Mould T., Hartley J. Enhanced repair of DNA interstrand crosslinking in ovarian cancer cells from patients following treatment with platinum-based chemotherapy. Br. J. Cancer 2007, 97:927-933.
30. Clingen P., Wu J., Miller J., Mistry N., Chin F., Wynne P., Prise K., Hartley J. Histone H2AX phosphorylation as a molecular pharmacological marker for DNA interstrand crosslink cancer chemotherapy. Biochem. Pharmacol. 2008, 76:19-27.
31. Vaisman A., Varchenko M., Umar A., Kunkel T.A., Risinger J.I., Barrett J.C., Hamilton T.C., Chaney S.G. The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: correlation with replicative bypass of platinum-DNA adducts. Cancer Res. 1998, 58:3579-3585.
32. Yang G.Z., Scherer S.J., Shell S.S., Yang K., Kim M., Lipkin M., Kucherlapati R., Kolodner R.D., Edelmann W. Dominant effects of an Msh6 missense mutation on DNA repair and cancer susceptibility. Cancer Cell 2004, 6:139-150.
33. Parker R.J., Eastman A., Bostick-Bruton F., Reed E. Acquired cisplatin resistance in human ovarian cancer cells is associated with enhanced repair of cisplatin-DNA lesions and reduced drug accumulation. J. Clin. Invest. 1991, 87:772-777.
34. Genschel J., Littman S.J., Drummond J.T., Modrich P. Isolation of MutSbeta from human cells and comparison of the mismatch repair specificities of MutSbeta and MutSalpha. J. Biol. Chem. 1998, 273:19895-19901.
35. Bronner C.E., Baker S.M., Morrison P.T., Warren G., Smith L.G., Lescoe M.K., Kane M., Earabino C., Lipford J., Lindblom A., Tannergard P., Bollag R.J., Godwin A.R., Ward D.C., Nordenskjold M., Fishel R., Kolodner R., Liskay R.M. Mutation in the DNA mismatch repair gene homolog hmlh1 is associated with hereditary nonpolyposis colon-cancer. Nature 1994, 368:258-261.
36. Ellison A.R., Lofing J., Bitter G.A. Human MutL homolog (MLH1) function in DNA mismatch repair: a prospective screen for missense mutations in the ATPase domain. Nucleic Acids Res. 2004, 32:5321-5338.
37. Topping R.P., Wilkinson J.C., Scarpinato K.D. Mismatch repair protein deficiency compromises cisplatin-induced apoptotic signaling. J. Biol. Chem. 2009, 284:14029-14039.
38. Shimodaira H., Yoshioka-Yamashita A., Kolodner R.D., Wang J.Y.J. Interaction of mismatch repair protein PMS2 and the p53-related transcription factor p73 in apoptosis response to cisplatin. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:2420-2425.
39. Marinovic-Terzic I., Yoshioka-Yamashita A., Shimodaira H., Avdievich E., Hunton I.C., Kolodner R.D., Edelmann W., Wang J.Y. Apoptotic function of human PMS2 compromised by the nonsynonymous single-nucleotide polymorphic variant R20Q. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:13993-13998.
40. Tomer G., Buermeyer A.B., Nguyen M.M., Liskay R.M. Contribution of human mlh1 and pms2 ATPase activities to DNA mismatch repair. J. Biol. Chem. 2002, 277:21801-21809.
41. Raevaara T.E., Korhonen M.K., Lohi H., Hampel H., Lynch E., Lonnqvist K.E., Holinski-Feder E., Sutter C., McKinnon W., Duraisamy S., Gerdes A.M., Peltomaki P., Kohonen-Ccorish M., Mangold E., Macrae F., Greenblatt M., de la Chapelle A., Nystrom M. Functional significance and clinical phenotype of nontruncating mismatch repair variants of MLH1. Gastroenterology 2005, 129:537-549.
42. Usanova S., Piee-Staffa A., Sied U., Thomale J., Schneider A., Kaina B., Koeberle B. Cisplatin sensitivity of testis tumour cells is due to deficiency in interstrand-crosslink repair and low ERCC1-XPF expression. Mol. Cancer 2010, 9.
43. Arora S., Kothandapani A., Tillison K., Kalman-Maltese V., Patrick S.M. Downregulation of XPF-ERCC1 enhances cisplatin efficacy in cancer cells. DNA Repair 2010, 9:745-753.